SmallLogo_edited.png

Transforming science into health

 TECHNOLOGY

ImunoTera offers an unprecedented biotech platform capable of restoring and activating immune system functions.  

 

The platform, called Act-Tera, is based on a recombinant protein designed with high therapeutic precision to fight different types of cancer.

 

Our first product, the TERAH-7 protein, targets precancerous lesions and cancer related to the human papilloma virus, HPV. How it works:

image3.jpeg
 

The Act-Tera platform is versatile and works as a therapeutic vaccine, which can be applied by different immunological strategies.

OUR PLATFORM

Prancheta 1-8.png
PROTEINA.png
5GM6_icn3d_loadable (2).png
DNA.png

MECHANISMS OF ACTION

With 100% Brazilian technology, the therapeutic vaccine increases the body's natural defenses against cancer, through three mechanisms:

image0 (1).jpeg

EFFICACY

ImunoTera's therapeutic vaccine showed synergism with other treatments, such as chemotherapy, with high efficacy in fighting HPV-induced cancer in the pre-clinical phase.
 

IMG_0764_edited.jpg
 

WHO WE ARE

Foto 0659 com corte e luz1.JPG

Luana Raposo de Melo

Industrial Pharmacist (UFF)
Master's Degree in Biological Sciences (USP)
Doctorate in Biological Sciences (USP)

MBA in Health Innovation Management
The Science and Business of Biotechnology (MIT)

BRU SITE.JPG

Bruna Maldonado Porchia

Biologist (UNESP)
Master's Degree in Biotechnology (USP)
Doctorate in Biological Sciences (USP)
Postdoctoral Immunology (USP)
Clinical Research Specialization (Invitare)

 

Mariana de Oliveira Diniz

Biologist (USP)
Doctorate in Biotechnology (USP/U. Penn., USA)
Postdoctoral Biological Sciences (USP)
Postdoctoral (Université Paris-Descartes)
Postdoctoral (University College London)

mariana diniz_edited.png

Timeline

Timeline english.png

Events and Awards

1.png
 
 
 

WHERE WE ARE